Edition:
United States

Cellectis SA (CLLS.OQ)

CLLS.OQ on NASDAQ Stock Exchange Global Market

25.28USD
3:16pm EST
Change (% chg)

$0.37 (+1.49%)
Prev Close
$24.91
Open
$25.08
Day's High
$25.45
Day's Low
$24.90
Volume
32,172
Avg. Vol
72,072
52-wk High
$35.07
52-wk Low
$16.33

Select another date:

Mon, Dec 4 2017

BRIEF-Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer

* CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Cellectis shares slump as death puts cell therapy tests on hold

LONDON French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death.

UPDATE 1-Cellectis shares slump as death puts cell therapy tests on hold

LONDON, Sept 5 French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death.

BRIEF-Cellectis says FDA places clinical hold of UCART123 studies following fatality

* ANNOUNCED TODAY HAVING RECEIVED NOTICE FROM FDA THAT CLINICAL HOLD WAS PLACED ON BOTH UCART123 ONGOING PHASE 1 STUDIES IN ACUTE MYELOID LEUKEMIA (AML) AND IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

BRIEF-Cellectis announces first patient dosed in clinical trial on UCART123

* ANNOUNCED ON THURSDAY, UCART123'S ADMINISTRATION TO FIRST PATIENT WITH BPDCN IN PHASE I CLINICAL TRIAL AT MD ANDERSON CANCER CENTER

BRIEF-Cellectis reports Q2 operating loss of 18.0 million euros

* SAID ON WEDNESDAY FIRST AML PATIENT TREATED WITH UCART123 ENROLLMENT ONGOING

BRIEF-Molmed signs development and production agreement with Cellectis

* SIGNS WITH CELLECTIS AGREEMENT FOR DEVELOPMENT AND PRODUCTION IN THE FIELD OF ALLOGENEIC CAR-T PRODUCTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cellectis is granted patent for CRISPR use in T-cells

* ANNOUNCED ON MONDAY ABOUT THE GRANT BY THE EUROPEAN PATENT OFFICE OF PATENT NO. EP3004337 FOR THE INVENTION OF USING RNA-GUIDED ENDONUCLEASES, SUCH AS CAS9 OR CPF1 FOR THE GENETIC ENGINEERING OF T-CELLS

BRIEF-Cellectis announces subsidiary's Calyxt’s IPO

* ANNOUNCES SUBSIDIARY'S CALYXT’S INITIAL PUBLIC OFFERING OF 7,000,000 SHARES

BRIEF-Cellectis announces proposed Calyxt IPO of $100.0 million

* CELLECTIS: CALYXT ANNOUNCES PROPOSED INITIAL PUBLIC OFFERING OF $100.0 MILLION

Select another date: